Bright Minds Biosciences (DRUG) said Tuesday that its BMB-101 showed a complete elimination of drop attacks in the DBA/2 mouse model of epilepsy.
"Notably, BMB-101 achieved 100% survival in the DBA/2 model, reversing brainstem serotonin deficits and preventing seizure-induced respiratory arrest," Jan Torleif Pedersen, the company's chief science officer, said.
The company said the findings demonstrate the potential of BMB-101 to address critical gaps in the prevention of sudden unexpected death in epilepsy.
Shares of Bright Minds Biosciences rose more than 11% in recent trading.
Price: 36.43, Change: +3.81, Percent Change: +11.68
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.